Cabotegravir implant (Preclinical)
Status:Completed
Phase:Pre-clinical
Principal Investigator(s):Patrick F. Kiser
Objective:The design, formulation development, and initial pharmacokinetic studies in non-human primates (NHP) on a cabotegravir subcutaneous reservoir implant. Part of SLAP HIV research program at Northwestern University.
Results summary: In 90 days we observed implant B release 11% of the total cabotegravir load suggesting these implants could deliver cabotegravir for a year in the nonhuman primate model. All components used in this implant have a history of previous human use in parenteral products. The CAB drug loading is high (~87% by weight), allowing efficient use of the implant volume.
Last updated October 20, 2022
Prevention Option(s):Microbicides, PrEP
Study Design:
Arms and Assigned Interventions
Description
Mode of DeliveryVaginal Insert
ARMs
Trial Sponsors:
NIAID
Start Date
End Date
none
none
Enrollment:0
Age range:
↔
any
Population:Cisgender Men